These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis. Saharan VD; Mahajan SS Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201 [TBL] [Abstract][Full Text] [Related]
32. Microwave-assisted organic synthesis, antimycobacterial activity, structure-activity relationship and molecular docking studies of some novel indole-oxadiazole hybrids. Desai NC; Somani HC; Mehta HK; Jadeja DJ; Khasiya AG; Khedkar VM SAR QSAR Environ Res; 2022 Feb; 33(2):89-109. PubMed ID: 35102805 [TBL] [Abstract][Full Text] [Related]
33. Novel 2-Nitroimidazole and Imidazooxazole Derivatives and their Activity against Trypanosoma cruzi and Mycobacterium tuberculosis. Faria JV; Passos FPZ; da Costa PHA; de Oliveira AP; Cruz YODD; Castelo-Branco FS; Lourenço MCS; Murta SMF; Junior PAS; Bernardino AMR; Bastos MM; Boechat N Med Chem; 2022; 18(6):701-709. PubMed ID: 34784878 [TBL] [Abstract][Full Text] [Related]
34. Computational studies of the properties and activities of selected trisubstituted benzimidazoles as potential antitubercular drugs inhibiting MTB-FtsZ polymerization. Akinpelu OI; Lawal MM; Kumalo HM; Mhlongo NN J Biomol Struct Dyn; 2022 Mar; 40(4):1558-1570. PubMed ID: 33021149 [TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis. Alsayed SSR; Lun S; Payne A; Bishai WR; Gunosewoyo H Bioorg Chem; 2021 Jan; 106():104486. PubMed ID: 33276981 [TBL] [Abstract][Full Text] [Related]
36. Synthesis of alkynylated 1,2,4-oxadiazole/1,2,3-1H-triazole glycoconjugates: Discovering new compounds for use in chemotherapy against lung carcinoma and Mycobacterium tuberculosis. Melo de Oliveira VN; Flávia do Amaral Moura C; Peixoto ADS; Gonçalves Ferreira VP; Araújo HM; Lapa Montenegro Pimentel LM; Pessoa CDÓ; Nicolete R; Versiani Dos Anjos J; Sharma PP; Rathi B; Pena LJ; Rollin P; Tatibouët A; Nascimento de Oliveira R Eur J Med Chem; 2021 Aug; 220():113472. PubMed ID: 33940463 [TBL] [Abstract][Full Text] [Related]
37. Bis-spirochromanones as potent inhibitors of Mycobacterium tuberculosis: synthesis and biological evaluation. Dongamanti A; Aamate VK; Devulapally MG; Gundu S; Balabadra S; Manga V; Yogeeswari P; Sriram D; Balasubramanian S Mol Divers; 2017 Nov; 21(4):999-1010. PubMed ID: 28840414 [TBL] [Abstract][Full Text] [Related]
38. Drug repurposing: Fusidic acid as a potential inhibitor of M. tuberculosis FtsZ polymerization - Insight from DFT calculations, molecular docking and molecular dynamics simulations. Akinpelu OI; Lawal MM; Kumalo HM; Mhlongo NN Tuberculosis (Edinb); 2020 Mar; 121():101920. PubMed ID: 32279872 [TBL] [Abstract][Full Text] [Related]